Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon

Seong Hee Kang, Moonyoung Kim, Soonkoo Baik

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Portal hypertension (PH) is responsible for the most severe complications of cirrhosis and leading cause of death and liver transplantation. The standard pharmacological treatment available for PH currently consists of the use of a non-selective beta-blocker. However, a significant proportion of patients do not respond to pharmacological treatment. This has led to the development of identifiable targets for the discovery of new horizons in PH treatment. Recently, there has been significant progress in understanding the mechanism behind PH, which is a product of increased hepatic vascular resistance including structural changes and functional change due to endothelial dysfunction. Moreover, increased portal inflow is the outcome of dilation of splanchnic vessels and hyperdynamic circulation. Here, challenges in formulating potential pharmacological treatment as well as current potential targets for PH will be reviewed. During the past decades, there have been many efforts to explore new techniques to stimulate liver regeneration in addition to pharmacological treatment. The bone marrow (BM) stem cells which differentiate into mature hepatocytes are thought to contribute to liver regeneration and have been found to demonstrate great potential as regenerative medicine in different therapeutic applications. Based on these insights, we explore the current and potential novel therapeutic uses of BM stem cell therapy in PH.

Original languageEnglish
Pages (from-to)112-121
Number of pages10
JournalHepatology International
Volume12
DOIs
Publication statusPublished - 2018 Feb 1

Fingerprint

Portal Hypertension
Pharmacology
Liver Regeneration
Bone Marrow Cells
Stem Cells
Therapeutics
Regenerative Medicine
Viscera
Therapeutic Uses
Cell- and Tissue-Based Therapy
Vascular Resistance
Liver Transplantation
Dilatation
Cause of Death
Hepatocytes
Fibrosis
Liver

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

@article{99adff38ac954266aad033b11584aed1,
title = "Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon",
abstract = "Portal hypertension (PH) is responsible for the most severe complications of cirrhosis and leading cause of death and liver transplantation. The standard pharmacological treatment available for PH currently consists of the use of a non-selective beta-blocker. However, a significant proportion of patients do not respond to pharmacological treatment. This has led to the development of identifiable targets for the discovery of new horizons in PH treatment. Recently, there has been significant progress in understanding the mechanism behind PH, which is a product of increased hepatic vascular resistance including structural changes and functional change due to endothelial dysfunction. Moreover, increased portal inflow is the outcome of dilation of splanchnic vessels and hyperdynamic circulation. Here, challenges in formulating potential pharmacological treatment as well as current potential targets for PH will be reviewed. During the past decades, there have been many efforts to explore new techniques to stimulate liver regeneration in addition to pharmacological treatment. The bone marrow (BM) stem cells which differentiate into mature hepatocytes are thought to contribute to liver regeneration and have been found to demonstrate great potential as regenerative medicine in different therapeutic applications. Based on these insights, we explore the current and potential novel therapeutic uses of BM stem cell therapy in PH.",
author = "Kang, {Seong Hee} and Moonyoung Kim and Soonkoo Baik",
year = "2018",
month = "2",
day = "1",
doi = "10.1007/s12072-017-9806-1",
language = "English",
volume = "12",
pages = "112--121",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",

}

Novelties in the pathophysiology and management of portal hypertension : new treatments on the horizon. / Kang, Seong Hee; Kim, Moonyoung; Baik, Soonkoo.

In: Hepatology International, Vol. 12, 01.02.2018, p. 112-121.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Novelties in the pathophysiology and management of portal hypertension

T2 - new treatments on the horizon

AU - Kang, Seong Hee

AU - Kim, Moonyoung

AU - Baik, Soonkoo

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Portal hypertension (PH) is responsible for the most severe complications of cirrhosis and leading cause of death and liver transplantation. The standard pharmacological treatment available for PH currently consists of the use of a non-selective beta-blocker. However, a significant proportion of patients do not respond to pharmacological treatment. This has led to the development of identifiable targets for the discovery of new horizons in PH treatment. Recently, there has been significant progress in understanding the mechanism behind PH, which is a product of increased hepatic vascular resistance including structural changes and functional change due to endothelial dysfunction. Moreover, increased portal inflow is the outcome of dilation of splanchnic vessels and hyperdynamic circulation. Here, challenges in formulating potential pharmacological treatment as well as current potential targets for PH will be reviewed. During the past decades, there have been many efforts to explore new techniques to stimulate liver regeneration in addition to pharmacological treatment. The bone marrow (BM) stem cells which differentiate into mature hepatocytes are thought to contribute to liver regeneration and have been found to demonstrate great potential as regenerative medicine in different therapeutic applications. Based on these insights, we explore the current and potential novel therapeutic uses of BM stem cell therapy in PH.

AB - Portal hypertension (PH) is responsible for the most severe complications of cirrhosis and leading cause of death and liver transplantation. The standard pharmacological treatment available for PH currently consists of the use of a non-selective beta-blocker. However, a significant proportion of patients do not respond to pharmacological treatment. This has led to the development of identifiable targets for the discovery of new horizons in PH treatment. Recently, there has been significant progress in understanding the mechanism behind PH, which is a product of increased hepatic vascular resistance including structural changes and functional change due to endothelial dysfunction. Moreover, increased portal inflow is the outcome of dilation of splanchnic vessels and hyperdynamic circulation. Here, challenges in formulating potential pharmacological treatment as well as current potential targets for PH will be reviewed. During the past decades, there have been many efforts to explore new techniques to stimulate liver regeneration in addition to pharmacological treatment. The bone marrow (BM) stem cells which differentiate into mature hepatocytes are thought to contribute to liver regeneration and have been found to demonstrate great potential as regenerative medicine in different therapeutic applications. Based on these insights, we explore the current and potential novel therapeutic uses of BM stem cell therapy in PH.

UR - http://www.scopus.com/inward/record.url?scp=85023190173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023190173&partnerID=8YFLogxK

U2 - 10.1007/s12072-017-9806-1

DO - 10.1007/s12072-017-9806-1

M3 - Review article

C2 - 28698986

AN - SCOPUS:85023190173

VL - 12

SP - 112

EP - 121

JO - Hepatology International

JF - Hepatology International

SN - 1936-0533

ER -